Get AUVI-Q for $0 out-of-pocket

Eligibility details

Anaphylaxis in infants and toddlers:
The rising rates and treatment challenges.

Not only can anaphylaxis be difficult to identify in infants and toddlers, but many caregivers are often unprepared to treat an allergic emergency. Learn more about the special challenges associated with this patient group.

Anaphylaxis has increased among infants and toddlers.

In a study of more than 56,000 emergency department visits for anaphylaxis in the United States from 2005 to 2014, the overall increase in the rate of visits for children aged 0 to 4 years was almost 130%.20

In a study describing age-related patterns in the symptoms of children (≤18 years) presenting with food-related allergic reactions at 2 emergency departments over 6 years, the largest proportion of patients with symptoms of anaphylaxis were younger than 2 years old.21

20 20

*Over the study period, from 14.2 ED visits per 100,000 enrollees in 2005 to 28.6 per 100,000 in 2014 (P<0.001 for trend).

Medical records collected from Jan 2001 to Dec 2006 for 1255 patients were reviewed.

It may be difficult to recognize symptoms of anaphylaxis in infants.18

Anaphylaxis can be difficult to identify in infants and toddlers, especially because they cannot describe subjective symptoms such as itching, throat tightness, or chest tightness.18

Signs of anaphylaxis in infants may include18:

baby

Learn more about the features of AUVI-q® (epinephrine injection, USP) 0.1 mg.

Learn more

Indication

AUVI-Q® (epinephrine injection, USP) is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of anaphylactic reactions or who are at increased risk for anaphylaxis.

Important Safety Information

AUVI-Q is intended for immediate self-administration as emergency supportive therapy only and is not a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. Each AUVI-Q contains a single dose of epinephrine for single-use injection. More than two sequential doses of epinephrine should only be administered under direct medical supervision. Since the doses of epinephrine delivered from AUVI-Q are fixed, consider using other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.

AUVI-Q should ONLY be injected into the anterolateral aspect of the thigh. Do not inject intravenously, or into buttock, digits, hands, or feet. Instruct caregivers to hold the leg of young children and infants firmly in place and limit movement prior to and during injection to minimize the risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Epinephrine should be administered with caution to patients with certain heart diseases, and in patients who are on medications that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or taking cardiac glycosides or diuretics. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.